The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis

Pediatric Surgery International

Volumn 29, Issue 2, 2013, Pages 101-119

  Domingo Fernandez, Raquel ^a,b   Watters, Karen ^a,b   Piskareva, Olga ^a,b   Stallings, Raymond L ^a,b   Bray, Isabella ^a,b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

Author keywords

ALK; DNA methylation; MiRNA; MYCN; Neuroblastoma; PTPRD

Indexed keywords

LONG UNTRANSLATED RNA; MESSENGER RNA; MICRORNA; RNA BINDING PROTEIN;

CHROMOSOME 11Q; CHROMOSOME 1P; CHROMOSOME ABERRATION; CHRONOLOGY; DISEASE PREDISPOSITION; DNA METHYLATION; EPIGENETICS; GENE DELETION; GENE MAPPING; GENE MUTATION; HEREDITY; HUMAN; NEUROBLASTOMA; ONCOGENE; OUTCOME ASSESSMENT; PHENOTYPE; PLOIDY; PRIORITY JOURNAL; REVIEW;

CHILD; CHROMOSOME DELETION; CHROMOSOME MAPPING; EPIGENOMICS; HUMANS; NEUROBLASTOMA;

EID: 84878358959     PISSN: 01790358     EISSN: 14379813     Source Type: Journal    
DOI: 10.1007/s00383-012-3239-7     Document Type: Review

References (227)

1. Spix C et al (2006) Neuroblastoma incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 42(13):2081-2091
2. Gurney JG et al (1995) Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer 75(8):2186-2195
3. Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3(3):203-216
4. Brodeur GM et al (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224(4653):1121-1124
5. Mosse YP et al (2004) Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet 75(4):727-730
6. Mosse YP et al (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455(7215):930-935
7. Chen Y et al (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455(7215):971-974
8. Stallings RL et al (2006) High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res 66(7):3673-3680
9. Molenaar JJ et al (2012) Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483(7391):589-593
10. Asgharzadeh S et al (2006) Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 98(17):1193-1203
11. Vermeulen J et al (2009) Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 10(7):663-671
12. De Preter K et al (2010) Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin Cancer Res 16(5):1532-1541
13. Oberthuer A et al (2008) Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR. Clin Cancer Res 14(20):6590-6601
14. Ohira M, Nakagawara A (2010) Global genomic and RNA profiles for novel risk stratification of neuroblastoma. Cancer Sci 101(11):2295-2301
15. Chen Y, Stallings RL (2007) Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 67(3):976-983
16. Bray I et al (2009) Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One 4(11):e7850
17. Cohn SL et al (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27(2):289-297
18. Kaneko Y et al (1987) Different karyotypic patterns in early and advanced stage neuroblastomas. Cancer Res 47(1):311-318
19. Brodeur GM, Nakagawara A (1992) Molecular basis of clinical heterogeneity in neuroblastoma. Am J Pediatr Hematol Oncol 14(2):111-116
20. Kaneko Y, Knudson AG (2000) Mechanism and relevance of ploidy in neuroblastoma. Genes Chromosomes Cancer 29(2):89-95
21. Brodeur GM et al (1997) Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol 19(2):93-101
22. Schleiermacher G et al (2012) Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer 107(8):1418-1422
23. Seeger RC et al (1985) Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313(18):1111-1116
24. Lutz W et al (1996) Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 13(4):803-812
25. Schweigerer L et al (1990) Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res 50(14):4411-4416
26. Knoepfler PS, Cheng PF, Eisenman RN (2002) N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev 16(20):2699-2712
27. Giannini G et al (2005) High mobility group A1 is a molecular target for MYCN in human neuroblastoma. Cancer Res 65(18):8308-8316
28. Shohet JM et al (2002) Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res 62(4):1123-1128
29. Slack A et al (2005) The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci USA 102(3):731-736
30. Chen L et al (2010) p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res 70(4):1377-1388
31. Manohar CF et al (2004) MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma. Oncogene 23(3):753-762
32. Weiss WA et al (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16(11):2985-2995
33. Edsjo A et al (2004) Neuroblastoma cells with overexpressed MYCN retain their capacity to undergo neuronal differentiation. Lab Invest 84(4):406-417
34. Chan HS et al (1997) MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res 3(10):1699-1706
35. Valentijn LJ et al (2012) Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci USA 109(47):19190-19195
36. Brodeur GM, Fong CT (1989) Molecular biology and genetics of human neuroblastoma. Cancer Genet Cytogenet 41(2):153-174
37. Brodeur GM et al (1981) Cytogenetic features of human neuroblastomas and cell lines. Cancer Res 41(11 Pt 1):4678-4686
38. Fong CT et al (1989) Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci USA 86(10):3753-3757
39. Attiyeh EF et al (2005) Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353(21):2243-2253
40. Martinsson T et al (1997) Delimitation of a critical tumour suppressor region at distal 1p in neuroblastoma tumours. Eur J Cancer 33(12):1997-2001
41. Bauer A et al (2001) Smallest region of overlapping deletion in 1p36 in human neuroblastoma: a 1 Mbp cosmid and PAC contig. Genes Chromosomes Cancer 31(3):228-239
42. Ohira M et al (2000) Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell line. Oncogene 19(37):4302-4307
43. Thompson PM et al (2003) CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 22(7):1002-1011
44. Fujita T et al (2008) CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 100(13):940-949
45. Koyama H et al (2012) Mechanisms of CHD5 inactivation in neuroblastomas. Clin Cancer Res 18(6):1588-1597
46. Henrich KO et al (2006) Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients. Clin Cancer Res 12(1):131-138
47. Henrich KO et al (2011) CAMTA1, a 1p36 tumor suppressor candidate, inhibits growth and activates differentiation programs in neuroblastoma cells. Cancer Res 71(8):3142-3151
48. Liu Z et al (2011) CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression. Cell Death Differ 18(7):1174-1183
49. Wang C et al (2012) EZH2 mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res 72(1):315-324
50. Krona C et al (2003) Screening for gene mutations in a 500 kb neuroblastoma tumor suppressor candidate region in chromosome 1p; mutation and stage-specific expression in UBE4B/UFD2. Oncogene 22(15):2343-2351
51. Krona C et al (2004) A novel 1p36.2 located gene, APITD1, with tumour-suppressive properties and a putative p53-binding domain, shows low expression in neuroblastoma tumours. Br J Cancer 91(6):1119-1130
52. Guo C et al (1999) Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 18(35):4948-4957
53. Plantaz D et al (2001) Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer 91(5):680-686
54. Maris JM et al (2001) Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. Med Pediatr Oncol 36(1):24-27
55. Spitz R et al (2006) Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res 12(11 Pt 1):3368-3373
56. Michels E et al (2007) ArrayCGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer 46(12):1098-1108
57. Luttikhuis ME et al (2001) Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis. Br J Cancer 85(4):531-537
58. Caren H et al (2010) High-risk neuroblastoma tumors with 11q- deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci USA 107(9):4323-4328
59. Celeste A et al (2003) H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell 114(3):371-383
60. Nowacki S et al (2008) Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma. Oncogene 27(23):3329-3338
61. Michels E et al (2008) CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23. BMC Cancer 8:173
62. Ando K et al (2008) Expression of TSLC1, a candidate tumor suppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation. Int J Cancer 123(9):2087-2094
63. Bown NP, Pearson AD, Reid MM (1993) High incidence of constitutional balanced translocations in neuroblastoma. Cancer Genet Cytogenet 69(2):166-167
64. Koiffmann CP et al (1995) Neuroblastoma in a boy with MCA/MR syndrome, deletion 11q, and duplication 12q. Am J Med Genet 58(1):46-49
65. Schulte JH et al (2010) Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int J Cancer 127(10):2374-2385
66. Meddeb M et al (1996) Additional copies of a 25 Mb chromosomal region originating from 17q23.1-17qter are present in 90 % of high-grade neuroblastomas. Genes Chromosomes Cancer 17(3):156-165
67. Caron H (1995) Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol 24(4):215-221
68. Bown N et al (1999) Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340(25):1954-1961
69. Van Roy N et al (1995) Molecular cytogenetic analysis of 1;17 translocations in neuroblastoma. Eur J Cancer 31A(4):530-535
70. Lastowska M et al (1997) Promiscuous translocations of chromosome arm 17q in human neuroblastomas. Genes Chromosomes Cancer 19(3):143-149
71. Savelyeva L, Corvi R, Schwab M (1994) Translocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells. Am J Hum Genet 55(2):334-340
72. McConville CM et al (2001) Molecular cytogenetic characterization of two non-MYCN amplified neuroblastoma cell lines with complex t(11;17). Cancer Genet Cytogenet 130(2):133-140
73. Stark B et al (2003) der(11)t(11;17): a distinct cytogenetic pathway of advanced stage neuroblastoma (NBL) - detected by spectral karyotyping (SKY). Cancer Lett 197(1-2):75-79
74. Stallings RL et al (2004) Molecular cytogenetic analysis of recurrent unbalanced t(11;17) in neuroblastoma. Cancer Genet Cytogenet 154(1):44-51
75. Schleiermacher G et al (2004) Variety and complexity of chromosome 17 translocations in neuroblastoma. Genes Chromosomes Cancer 39(2):143-150
76. Spitz R et al (2003) Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma. Clin Cancer Res 9(13):4835-4840
77. Brinkschmidt C et al (1997) Comparative genomic hybridization (CGH) analysis of neuroblastomas - an important methodological approach in paediatric tumour pathology. J Pathol 181(4):394-400
78. Buckley PG et al (2010) Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma. Clin Cancer Res 16(11):2971-2978
79. Claviez A et al (2004) Low occurrence of familial neuroblastomas and ganglioneuromas in five consecutive GPOH neuroblastoma treatment studies. Eur J Cancer 40(18):2760-2765
80. Maris JM et al (1997) Molecular genetic analysis of familial neuroblastoma. Eur J Cancer 33(12):1923-1928
81. Pattyn A et al (2000) Control of hindbrain motor neuron differentiation by the homeobox gene Phox2b. Development 127(7):1349-1358
82. Raabe EH et al (2008) Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene 27(4):469-476
83. van Limpt V et al (2004) The Phox2B homeobox gene is mutated in sporadic neuroblastomas. Oncogene 23(57):9280-9288
84. Mano H (2012) ALKoma: a cancer subtype with a shared target. Cancer Discov 2(6):495-502
85. Azarova AM, Gautam G, George RE (2011) Emerging importance of ALK in neuroblastoma. Semin Cancer Biol 21(4):267-275
86. Heukamp LC et al (2012) Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice. Sci Transl Med 4(141):141ra91
87. Capasso M et al (2009) Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet 41(6):718-723
88. Wang K et al (2011) Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature 469(7329):216-220
89. Maris JM et al (2008) Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med 358(24):2585-2593
90. Wu LC et al (1996) Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 14(4):430-440
91. Stephens PJ et al (2011) Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144(1):27-40
92. Diskin SJ et al (2012) Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet 44(10):1126-1130
93. Molenaar JJ et al (2012) LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet 44(11):1199-1206
94. Fischer M et al (2006) Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clin Cancer Res 12(17):5118-5128
95. Berwanger B et al (2002) Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell 2(5):377-386
96. Oberthuer A et al (2006) Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 24(31):5070-5078
97. Ohira M et al (2005) Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 7(4):337-350
98. Wang Q et al (2006) Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 66(12):6050-6062
99. Abel F et al (2011) A 6-gene signature identifies four molecular subgroups of neuroblastoma. Cancer Cell Int 11:9
100. Fischer M et al (2009) Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q. Oncogene 29:865-875
101. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5):843-854
102. Hebert SS, De Strooper B (2007) Molecular biology. miRNAs in neurodegeneration. Science 317(5842):1179-1180
103. Iorio MV et al (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65(16):7065-7070
104. Miska EA (2005) How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 15(5):563-568
105. Kapsimali M et al (2007) MicroRNAs show a wide diversity of expression profiles in the developing and mature central nervous system. Genome Biol 8(8):R173
106. Lu J et al (2005) MicroRNA expression profiles classify human cancers. Nature 435(7043):834-838
107. Schulte JH et al (2008) MYCN regulates oncogenic microRNAs in neuroblastoma. Int J Cancer 122(3):699-704
108. Fontana L et al (2008) Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 3(5):e2236
109. Mestdagh P et al (2010) The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol Cell 40(5):762-773
110. De Brouwer S et al (2012) Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma. Int J Cancer 130(11):2591-2598
111. Buechner J et al (2011) Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer 105(2):296-303
112. Welch C, Chen Y, Stallings RL (2007) MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26(34):5017-5022
113. Tivnan A et al (2011) MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer 11:33
114. Cole KA et al (2008) A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res 6(5):735-742
115. Lynch J et al (2012) MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-beta signalling pathway. Carcinogenesis 33(5):976-985
116. Bray I et al (2011) MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. Cancer Lett 303(1):56-64
117. Laneve P et al (2007) The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. Proc Natl Acad Sci USA 104(19):7957-7962
118. Le MT et al (2009) MicroRNA-125b promotes neuronal differentiation in human cells by repressing multiple targets. Mol Cell Biol 29(19):5290-5305
119. Foley NH et al (2011) MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2. Cell Death Differ 18(7):1089-1098
120. Ryan J et al (2012) MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer 107(6):967-976
121. Calin GA et al (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101(9):2999-3004
122. Chang TC et al (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26(5):745-752
123. Wei JS et al (2008) The MYCN oncogene is a direct target of miR-34a. Oncogene 27(39):5204-5213
124. Tivnan A et al (2012) Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One 7(5):e38129
125. Bommer GT et al (2007) p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17(15):1298-1307
126. Sun F et al (2008) Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett 582(10):1564-1568
127. Atroshchenko ES et al (1991) Effect of xanthinol niacinate on the autoimmunity and capillary permeability in patients with stable stenocardia. Kardiologiia 31(3):18-21
128. Pang RT et al (2010) MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis 31(6):1037-1044
129. Brodeur GM et al (1988) International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 6(12):1874-1881
130. Mestdagh P et al (2010) MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 29(9):1394-1404
131. Murphy DM et al (2009) Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. PLoS One 4(12):e8154
132. Corcoran DL et al (2009) Features of mammalian microRNA promoters emerge from polymerase II chromatin immunoprecipitation data. PLoS One 4(4):e5279
133. Shohet JM et al (2011) A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Cancer Res 71(11):3841-3851
134. Hayashita Y et al (2005) A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 65(21):9628-9632
135. Busacca S et al (2009) MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol 42:312-319
136. Yu Z et al (2008) A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol 182(3):509-517
137. Mraz M et al (2009) MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk Lymphoma 50(3):506-509
138. Takakura S et al (2008) Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci 99(6):1147-1154
139. O'Donnell KA et al (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435(7043):839-843
140. He L et al (2007) A microRNA component of the p53 tumour suppressor network. Nature 447(7148):1130-1134
141. Braun CJ et al (2008) p53-Responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 68(24):10094-10104
142. Sachdeva M et al (2009) p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 106(9):3207-3212
143. Georges SA et al (2008) Coordinated regulation of cell cycle transcripts by p53-inducible microRNAs, miR-192 and miR-215. Cancer Res 68(24):10105-10112
144. Feng Z et al (2011) Tumor suppressor p53 meets microRNAs. J Mol Cell Biol 3(1):44-50
145. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88(3):323-331
146. Carr-Wilkinson J et al (2010) High frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma. Clin Cancer Res 16(4):1108-1118
147. Momand J et al (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69(7):1237-1245
148. Slack A, Shohet JM (2005) MDM2 as a critical effector of the MYCN oncogene in tumorigenesis. Cell Cycle 4(7):857-860
149. Alaminos M et al (2004) Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst 96(16):1208-1219
150. Astuti D et al (2001) RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene 20(51):7573-7577
151. Banelli B et al (2002) Expression and methylation of CASP8 in neuroblastoma: identification of a promoter region. Nat Med 8(12):1333-1335 (author reply 1335)
152. Yang Q et al (2007) Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res 13(11):3191-3197
153. van Noesel MM et al (2003) Clustering of hypermethylated genes in neuroblastoma. Genes Chromosomes Cancer 38(3):226-233
154. Decock A et al (2011) Neuroblastoma epigenetics: from candidate gene approaches to genome-wide screenings. Epigenetics 6(8):962-970
155. Grau E et al (2011) Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease. Mol Carcinog 50(3):153-162
156. Michalowski MB et al (2008) Methylation of tumor-suppressor genes in neuroblastoma: the RASSF1A gene is almost always methylated in primary tumors. Pediatr Blood Cancer 50(1):29-32
157. Yagyu S et al (2008) Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma. Clin Cancer Res 14(21):7011-7019
158. Das S et al (2010) MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation. Cancer Res 70(20):7874-7881
159. Kunej T et al (2011) Epigenetic regulation of microRNAs in cancer: an integrated review of literature. Mutat Res 717(1-2):77-84
160. Das S et al (2012) Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs. Oncogene
161. Michlewski G et al (2008) Posttranscriptional regulation of miRNAs harboring conserved terminal loops. Mol Cell 32(3):383-393
162. Moss EG, Lee RC, Ambros V (1997) The cold shock domain protein LIN-28 controls developmental timing in C. elegans and is regulated by the lin-4 RNA. Cell 88(5):637-646
163. Boyerinas B et al (2008) Identification of let-7-regulated oncofetal genes. Cancer Res 68(8):2587-2591
164. Rybak A et al (2008) A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nat Cell Biol 10(8):987-993
165. Richards M et al (2004) The transcriptome profile of human embryonic stem cells as defined by SAGE. Stem Cells 22(1):51-64
166. Viswanathan SR, Daley GQ, Gregory RI (2008) Selective blockade of microRNA processing by Lin28. Science 320(5872):97-100
167. Newman MA, Thomson JM, Hammond SM (2008) Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA 14(8):1539-1549
168. Piskounova E et al (2011) Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell 147(5):1066-1079
169. Heo I et al (2009) TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation. Cell 138(4):696-708
170. Lehrbach NJ et al (2009) LIN-28 and the poly(U) polymerase PUP-2 regulate let-7 microRNA processing in Caenorhabditis elegans. Nat Struct Mol Biol 16(10):1016-1020
171. Hagan JP, Piskounova E, Gregory RI (2009) Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in mouse embryonic stem cells. Nat Struct Mol Biol 16(10):1021-1025
172. Yu J et al (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318(5858):1917-1920
173. Viswanathan SR et al (2009) Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 41(7):843-848
174. Iliopoulos D, Hirsch HA, Struhl K (2009) An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139(4):693-706
175. King CE et al (2011) LIN28B promotes colon cancer progression and metastasis. Cancer Res 71(12):4260-4268
176. Bejerano G et al (2004) Ultraconserved elements in the human genome. Science 304(5675):1321-1325
177. Calin GA et al (2007) Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 12(3):215-229
178. Mestdagh P et al (2010) An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours. Oncogene 29(24):3583-3592
179. Scaruffi P et al (2009) Transcribed-ultra conserved region expression is associated with outcome in high-risk neuroblastoma. BMC Cancer 9:441
180. Yu M et al (2009) High expression of ncRAN, a novel non-coding RNA mapped to chromosome 17q25.1, is associated with poor prognosis in neuroblastoma. Int J Oncol 34(4):931-938
181. Voth H et al (2007) Identification of DEIN, a novel gene with high expression levels in stage IVS neuroblastoma. Mol Cancer Res 5(12):1276-1284
182. Chooniedass-Kothari S et al (2004) The steroid receptor RNA activator is the first functional RNA encoding a protein. FEBS Lett 566(1-3):43-47
183. Candeias MM et al (2008) P53 mRNA controls p53 activity by managing Mdm2 functions. Nat Cell Biol 10(9):1098-1105
184. Gupta RA et al (2010) Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464(7291):1071-1076
185. Rinn JL et al (2007) Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 129(7):1311-1323
186. Abel F et al (2004) Mutations in the N-terminal domain of DFF45 in a primary germ cell tumor and in neuroblastoma tumors. Int J Oncol 25(5):1297-1302
187. le Nguyen B et al (2011) Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility loci. PLoS Genet 7(3):e1002026
188. Duijkers FA et al (2012) High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome. Am J Pathol 180(3):1223-1231
189. Bourdeaut F et al (2012) ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome. Eur J Hum Genet 20(3):291-297
190. de Pontual L et al (2011) Germline gain-of-function mutations of ALK disrupt central nervous system development. Hum Mutat 32(3):272-276
191. Devoto M et al (2011) Genome-wide linkage analysis to identify genetic modifiers of ALK mutation penetrance in familial neuroblastoma. Hum Hered 71(2):135-139
192. Passoni L et al (2009) Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res 69(18):7338-7346
193. Caren H et al (2008) High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 416(2):153-159
194. Janoueix-Lerosey I et al (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455(7215):967-970
195. George RE et al (2007) Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One 2(2):e255
196. Schulte JH et al (2011) High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res 17(15):5082-5092
197. Shukla N et al (2012) Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res 18(3):748-757
198. Perri P et al (2005) PHOX2B mutations and genetic predisposition to neuroblastoma. Oncogene 24(18):3050-3053
199. Bourdeaut F et al (2005) Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Cancer Lett 228(1-2):51-58
200. McConville C et al (2006) PHOX2B analysis in non-syndromic neuroblastoma cases shows novel mutations and genotype-phenotype associations. Am J Med Genet A 140(12):1297-1301
201. Ghiorzo P et al (2006) Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma. Hum Mol Genet 15(18):2682-2689
202. Obana K et al (2003) Aberrations of p16INK4A, p14ARF and p15INK4B genes in pediatric solid tumors. Int J Oncol 23(4):1151-1157
203. Caren H et al (2008) High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. BMC Genomics 9:353
204. Omura-Minamisawa M et al (2001) p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease. Clin Cancer Res 7(11):3481-3490
205. Molenaar JJ et al (2003) Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes Chromosomes Cancer 36(3):242-249
206. Martinelli S et al (2006) Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors. Cancer Genet Cytogenet 166(2):124-129
207. Mutesa L et al (2008) Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors. Cancer Genet Cytogenet 182(1):40-42
208. Origone P et al (2003) Homozygous inactivation of NF1 gene in a patient with familial NF1 and disseminated neuroblastoma. Am J Med Genet A 118A(4):309-313
209. Kong XT et al (1997) Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma. Cancer Res 57(17):3772-3778
210. Foley NH et al (2010) MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer 9:83
211. Le MT et al (2009) MicroRNA-125b is a novel negative regulator of p53. Genes Dev 23(7):862-876
212. Evangelisti C et al (2009) MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness. FASEB J 23(12):4276-4287
213. Lin RJ, Lin YC, Yu AL (2010) miR-149*induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Mol Carcinog 49(8):719-727
214. Chen H et al (2010) miR-7 and miR-214 are specifically expressed during neuroblastoma differentiation, cortical development and embryonic stem cells differentiation, and control neurite outgrowth in vitro. Biochem Biophys Res Commun 394(4):921-927
215. Meseguer S et al (2011) MicroRNAs-10a and -10b contribute to retinoic acid-induced differentiation of neuroblastoma cells and target the alternative splicing regulatory factor SFRS1 (SF2/ASF). J Biol Chem 286(6):4150-4164
216. Haug BH et al (2011) MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma. Carcinogenesis 32(7):1005-1012
217. Huang TC et al (2011) Silencing of miR-124 induces neuroblastoma SK-N-SH cell differentiation, cell cycle arrest and apoptosis through promoting AHR. FEBS Lett 585(22):3582-3586
218. Makeyev EV et al (2007) The microRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol Cell 27(3):435-448
219. Lee JJ et al (2012) MiR-27b targets PPARgamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene 31(33):3818-3825
220. Xu H et al (2009) MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res 69(15):6275-6281
221. Annibali D et al (2012) A new module in neural differentiation control: two microRNAs upregulated by retinoic acid, miR-9 and -103, target the differentiation inhibitor ID2. PLoS One 7(7):e40269
222. Zhang H et al (2012) MicroRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. Mol Cancer Ther 11(7):1454-1466
223. Moncini S et al (2011) The role of miR-103 and miR-107 in regulation of CDK5R1 expression and in cellular migration. PLoS ONE 6(5):e20038
224. Afanasyeva EA et al (2011) MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival. Cell Death Differ 18(6):974-984
225. Beveridge NJ et al (2009) Down-regulation of miR-17 family expression in response to retinoic acid induced neuronal differentiation. Cell Signal 21(12):1837-1845
226. Loven J et al (2010) MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. Proc Natl Acad Sci USA 107(4):1553-1558
227. Chayka O et al (2009) Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. J Natl Cancer Inst 101(9):663-677